Biogen’s Tecfidera Label Updated After Brain Infection Case

The label for Biogen Idec Inc.’s multiple sclerosis drug Tecfidera will be updated with information about a patient who died of a rare brain infection while taking the medicine, U.S. regulators said today.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.